Staphylococcus aureus bivalent (types 5 and 8) conjugate vaccine (Nabi)

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameStaphylococcus aureus bivalent (types 5 and 8) conjugate vaccine (Nabi)

Drug Alias NameS. aureus type 5 & 8 capsular polysaccharide conjugate vaccine - NabiStaphVAX-BivalentNabi-StaphVAXStaphylococcus aureus polysaccharide conjugate vaccine bivalent - Nabi

ClassificationVaccines > Biological material > Bacterial vaccineVaccines > Development/production technology > Conjugated vaccineVaccines > Application > Therapeutic vaccine

Mechanisms of ActionImmunostimulants

TargetsNot applicable

Therapy Area/IndicationsCardiovascular DiseasesKidney Failure, ChronicStaphylococcal Infections

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesUnited Kingdom

CombinationsNo

Global Highest StatusDiscontinued (Phase 3 Clinical)

Highest Status in ChinaN/A

Originator CompaniesNabi Biopharmaceuticals National Institutes Of Health

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesNabi Biopharmaceuticals

Active IndicationsN/A

Inactive IndicationsCardiovascular DiseasesKidney Failure, ChronicStaphylococcal Infections

Other Information

ATC CodeN/A